AzTrials
AzTrials

Breast FeedingNCT03337893

Investigation of Breastfeeding Protection Against Infant Infections and Childhood Diseases

An observational study of Breast Feeding and Disease, run by Yildiz Atadag at 1 site in Turkey (Türkiye).

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Objective: It is widely accepted that breastfeeding (AS) is superior to other forms of nutrition in the first six months of life. Breastmilk contains nutrient items in appropriate quantities and a high bioavailability according to the needs of each baby. Read more about this study

Who is it for?
Ages 5 to 5 years
Conditions the study is for
Breast Feeding, Disease
What is being tested?
blood pressure
How many people
500 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Oct 2017to 1 Apr 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 5 years
  • All sexes
  • Child

Study population: 5 year old kids

Who may be able to join

  • Being at the age of 5
  • birth weight between 2500 and 4000 grams
  • birth week is between 38-42 weeks

Who cannot join

  • Not being at the age of 5
  • birth week is not between 38-42 weeks
  • birth weight between 2500 and 4000 grams
  • having a serious illness e.g. cerebral palsy

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Gaziantep Sahinbey Baglarbasi Family Health Center

    Gaziantep

Other trials in Turkey (Türkiye)

About this study

Objective: It is widely accepted that breastfeeding (AS) is superior to other forms of nutrition in the first six months of life. Breastmilk contains nutrient items in appropriate quantities and a high bioavailability according to the needs of each baby. The United Nations Children's Fund (UNICEF) and the World Health Organization (WHO) recommend that babies take AS alone and then continue to feed on AS with up to two years of age, with appropriate supplementary nutrition, during the first six months of life.

Even in the hottest climates, breastfeeding babies have been shown to have no additional nutrient or fluid requirements for the first six months, including water. In the first 6 months of breastfeeding with breast milk alone (YAS), the incidence of many diseases, especially infectious diseases, decreases and the brain development is better.

Read more

Despite its numerous benefits, mother milk is not utilized in our country sufficiently. According to the Turkish Demographic and Health Survey (TNSA), the rate of breastfeeding in Turkey was 91.8% in Turkey, while the proportion of babies fed only breast milk in the first 6 months was 30.1%.

Infants related deaths, otitis media, lower respiratory tract infections, gastroenteritis, obesity were more common in children who were fed formula milk compared to children who were fed breast milk during the first year of life. Obesity can reduce insulin resistance and hypertension risks later in life.

According to the research done by Kramer and his colleagues on 13889 children, no effect of breastfeeding on physical development, obesity and hypertension was found.

In this study, whether breast feeding was associated with otitis media in the first year, lower respiratory tract infection, gastroenteritis; in the first 5 years of age, obesity and hypertension.

Read the detailed description

Method: This descriptive study will be conducted by Gaziantep Şahinbey Bağlarbaşı ASM, a 5-year-old children who applied between 01.10.2017 - 04.04.2018, with their weight and blood pressure measurements and their parents' questionnaires. Approximately 500 children will be taken to work. Informed consent is obtained from the parents of the patients who will be employed, and verbal consent is given from the children. Those who do not give their approval will not be included in the study. People with a known congenital disease, those with no birth week between 38 and 42 and a birth weight between 2500 and 4000 grams will not be included in the study.

The length measurement shall be made on a fixed scale, with the back of the head on a flat surface, with the head perpendicular, and with the eyes vertically facing (Frankfurt plane), the distance between the top of the head and the soles of the feet shall be a fixed scale or gauge. Blood pressure measurement will be measured by a digital blood pressure meter from the left and right hand (M6; Omron Healthcare).

Measurements of height, weight and hemoglobin in the past ages of the subjects taken in the study group will be taken from the computer programs used in the family medicine system. Percentile values of measurements belonging to each age group will also be recorded.

Being tested
blood pressure
Medical subject headings
Breast Feeding, Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • blood pressureDiagnostic test

    it will be done both right and left arms

Study groups in NCT03337893
Study groupRoleWhat they receive
BreastfedThe kids who breastfed
Receives: Diagnostic Test: blood pressure
non-breastfedThe kids who did not breastfed
Receives: Diagnostic Test: blood pressure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. BP

    Blood Pressure

    Measured: Baseline for age 5

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Nov 2017
  2. Study start1 Oct 2017
  3. Primary completion1 Apr 2018 (estimated)
  4. Study completion1 Apr 2018 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03337893
Sponsor's protocol ID
307
Status last verified
Nov 2017
First submitted
23 Oct 2017
Last updated
9 Nov 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Gökçay G, Garipağaoğlu M. Çocukluk ve Ergenlik Döneminde Beslenme. İstanbul: Saga Yayınları, 2002: 24-63.

  • Gökçay G, Garibağaoğlu M. Sağlıklı Çocuğun Beslenmesi. İçinde: Neyzi O, Ertuğrul T: Pediatri. 1. Cilt. İstanbul: Nobel Tıp Kitabevi, 2002: 183-202.

  • American Academy of Pediatrics. Nutrition and Immunitiy. Chapter 31. In: Pediatric Nutriton Handbook CD- ROM. 4 th ed. Elk Growe Village: Abbott Laboratories, 1998: 473-84.

  • Lawrens RA, Lawrence RM. Host-resistance factors and immunologic significance of human milk. In: Lawrens RA, Lawrence RM (eds). Breastfeeding. St. Louis: Mosby, 1994: 159-95.

  • T.C. Sağlık Bakanlığı, Hacettepe Üniversitesi Nüfus Etüdleri Enstitüsü. Türkiye Nüfus ve Sağlık Araştırması 2003. Ankara: Macro International Inc, 2003.

  • Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü (2014), "2013 Türkiye Nüfus ve Sağlık Araştırması". Hacettepe Üniversitesi Nüfus Etütleri Enstitüsü, T.C. Kalkınma Bakanlığı ve TÜBİTAK, Ankara, Türkiye

  • Stuebe A. The risks of not breastfeeding for mothers and infants. Rev Obstet Gynecol. 2009 Fall;2(4):222-31.

    PubMed 20111658
  • Kramer MS, Matush L, Vanilovich I, Platt RW, Bogdanovich N, Sevkovskaya Z, Dzikovich I, Shishko G, Collet JP, Martin RM, Davey Smith G, Gillman MW, Chalmers B, Hodnett E, Shapiro S; PROBIT Study Group. Effects of prolonged and exclusive breastfeeding on child height, weight, adiposity, and blood pressure at age 6.5 y: evidence from a large randomized trial. Am J Clin Nutr. 2007 Dec;86(6):1717-21. doi: 10.1093/ajcn/86.5.1717.

    PubMed 18065591
  • Mazıcıoğlu MM.Büyüme gelişme izleminde kullanılan antropometrik ölçüm yöntemleri: Büyüme takibinin metodolojisi.Türkiye Aile Hekimliği Dergisi 2011;15(3):101-108.

  • Altunkan S, Ilman N, Kayaturk N, Altunkan E. Validation of the Omron M6 (HEM-7001-E) upper-arm blood pressure measuring device according to the International Protocol in adults and obese adults. Blood Press Monit. 2007 Aug;12(4):219-25. doi: 10.1097/MBP.0b013e3280f813d0.

    PubMed 17625394
  • Coleman A, Freeman P, Steel S, Shennan A. Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press Monit. 2006 Feb;11(1):27-32. doi: 10.1097/01.mbp.0000189788.05736.5f.

    PubMed 16410738
  • Topouchian JA, El Assaad MA, Orobinskaia LV, El Feghali RN, Asmar RG. Validation of two automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension: the Omron M6 (HEM-7001-E) and the Omron R7 (HEM 637-IT). Blood Press Monit. 2006 Jun;11(3):165-71. doi: 10.1097/01.mbp.0000209078.17246.34.

    PubMed 16702826
  • World Health Organization, UNICEF. Global Strategy for Infant and Young Child Feeding, Geneva: WHO, 2003: 1-4, 7-9.

Questions about this trial

What is this clinical trial studying?

An observational study of Breast Feeding and Disease, run by Yildiz Atadag at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

BP (time frame: Baseline for age 5). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03337893, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in